■Boryung announced on the 4th that Samsung Bioepis officially launched the bone disease treatment drug "Xbric" in South Korea on the 1st. Xbric is a biosimilar (generic drug for biologics) of the original drug Xgeva and is used for the prevention of skeletal symptoms in patients with bone metastasis and the treatment of giant cell tumors of the bone. It received domestic item approval in May, and as of the 1st, it has been supplied with insurance coverage. Under the partnership agreement, Samsung Bioepis is responsible for development, production, and supply, while Boryung is in charge of domestic sales and marketing.
■Global robotics-assisted surgery system corporation Intuitive Surgical Korea announced on the 4th that it has launched the "Shape-Sensing Robotic Assisted Bronchoscopy" platform called Ion (hereinafter referred to as Ion). Ion is a robotic-assisted bronchoscopy system (Endoluminal System) that uses fiber optic sensing catheters and robot-assisted systems to confirm the location of lesions in real-time for tissue biopsies and localization procedures targeting lung cancer suspected or confirmed patients and patients with peripheral lung lesions.
■The pharmaceutical development corporation G2GBIO announced on the 4th that it has set the public offering price at 58,000 won. This is the upper limit of the desired price range for the public offering, which was 48,000 to 58,000 won. In the demand forecast held from the 25th to the 31st of last month, a total of 2,446 domestic and foreign institutional investors participated, recording a competition rate of 810.6 to 1.
■Daewoong Pharmaceutical Sun Village recommended an "all-inclusive forest vacation" for healthily escaping the summer heat on the 4th. According to the company, Sun Village is located in a forest at an altitude of 250 meters at the foot of Jongjasan Mountain in Hongcheon, Gangwon Province, where the average minimum temperature at night in summer remains below 24 degrees Celsius. This place is an "all-inclusive wellness resort" that includes accommodation, healthy meals, and yoga and meditation programs, providing low-sodium health dishes and balanced nutrition to help recover immunity. Visitors can relax their bodies and minds through forest meditation with professional healing coordinators and enjoy refreshing wine in the "forest wine cave (Seonhyang Cave)" that maintains a cool temperature of 13 to 15 degrees year-round among its facilities.
■NIBEC announced on the 4th that it has successfully completed clinical trials for its core bone regeneration material product "OCS-B Collagen" in China and submitted an application for product approval to the National Medical Products Administration (NMPA) of China. The company conducted this clinical trial involving a total of 192 patients at four major university hospitals in China, reporting that therapeutic effects were confirmed in all patients who applied NIBEC products and showed statistically equivalent levels of therapeutic efficacy and safety compared to products from other global companies.
■Peptide development corporation HLB Pep and sepsis new drug development corporation HLB Science announced on the 4th that they signed a "joint development agreement for antibacterial and antiviral peptide therapeutics" at the HLB Seoul office on the 1st. HLB Pep will intensify the development of the antibacterial peptide new drug "AGM-290" and antiviral therapeutic "AGM-380". HLB Science will fuse HLB Pep's new drug materials and technologies with existing antibacterial peptide technologies, accelerating the development of next-generation antibiotics and sepsis medications while expanding its business into various viral disease areas such as influenza and AIDS. HLB Science plans to transfer HLB Pep's technology after further proving efficacy and safety based on the relevant substances.
■Dong-A Pharmaceutical announced on the 4th that it has released a special edition in collaboration with the drink Bacchus F and game developer KRAFTON for the game "PUBG: Battlegrounds." The collaboration was applied to the label of Bacchus F bottles and the packaging of the 10-pack case, and there will be an item giveaway event for buyers of the 10-pack case to commemorate the collaboration. This product will be available for purchase until Nov. 30.
■GC Biopharma announced on the 4th that it conducted a symposium for the bowel cleansing agent "One Prep 1.38 Acid" at the Intercontinental Hotel in conjunction with Healthy Pharmaceuticals on the 26th of last month. Professor Kim Ji-won from Boramae Hospital in Seoul served as the moderator for this symposium. One Prep 1.38 Acid is an improved new drug jointly marketed by GC Biopharma and Healthy Pharmaceuticals since they signed a joint selling agreement in 2020. The minimum dosage is 1.38 liters, which should be taken in one go on the morning of the day without taking any the day before.